...
首页> 外文期刊>Cancer immunology, immunotherapy : >Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities
【24h】

Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities

机译:液体活检中改变组织周转的定量:一种提出的精密药物工具,用于评估与促癌性利基相关的慢性炎症和脱落,并对免疫治疗抗肿瘤方式的反应

获取原文
获取原文并翻译 | 示例
           

摘要

Immuno-therapy has begun to revolutionize cancer treatment. However, despite the significant progress achieved in regard to the duration of clinical benefits, a substantial number of patients do not respond to these therapies. To improve the outcome of patients receiving immuno-therapy, there is a need for novel biomarkers that can predict and monitor treatment. Tumor microenvironment alterations, more specifically the state of chronic inflammation and desmoplasia (tumor fibrosis), are important factors to consider in this context. Here, we discuss the potential for quantification of altered tissue turnover in a liquid biopsy as a proposed precision medicine tool to assess chronic inflammation and desmoplasia in the immuno-oncology (IO) setting. We highlight the need for novel non-invasive biomarkers in IO and the importance of addressing tumor microenvironment alterations. We focus on desmoplasia and extracellular matrix (ECM) remodeling, and how the composition of the ECM defines T-cell permissiveness in the tumor microenvironment and opens up the possibility for associated liquid biopsy biomarkers. Moreover, we address the importance of the assessment of chronic inflammation, primarily macrophage activity, in a liquid biopsy.
机译:免疫疗法已开始彻底改变癌症治疗。然而,尽管在临床效益的持续时间内实现了显着进展,但大量的患者不会对这些疗法进行响应。为了改善接受免疫疗法的患者的结果,需要一种可以预测和监测治疗的新型生物标志物。肿瘤微环境改变,更具体地说,慢性炎症和脱钙(肿瘤纤维化)是在这种情况下考虑的重要因素。在这里,我们讨论了在液检中定量改变的组织转换的可能性,作为提出的精密药物工具,以评估免疫肿瘤学(IO)设置中的慢性炎症和脱落。我们强调了IO新型非侵入性生物标志物的需求以及解决肿瘤微环境改变的重要性。我们专注于Desmoclasia和细胞外基质(ECM)重塑,以及ECM的组成如何定义肿瘤微环境中的T细胞允许,并打开相关液体活检生物标志物的可能性。此外,在液检中,我们解决了评估慢性炎症,主要是巨噬细胞活性的重要性。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号